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Abstract
Background: Deletion of 13q14 is the most common cytogenetic change in chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL) and is detected in about 50 % of patients by fluorescence in situ hybridization
(FISH), which can reveal presence of del(13)(q14) and mono- or biallelic deletion status without information about
the size of the lost region. Array-comparative genomic hybridization (aCGH) and single nucleotide polymorphism
(SNP) can detect submicroscopic copy number changes, loss of heterozygosity (LOH) and uniparental disomy (UPD)
regions. The purpose of this study was detection of the size of del(13)(q14) deletion in our group of patients,
comparing the size of the monoallelic and biallelic deletions, detection of LOH and UPD regions.
Results: We have investigated 40 CLL/SLL patients by karyotype, FISH and CGH and SNP array. Mutational status
was of immunoglobulin heavy-chain variable-region (IGVH) was also examined. The size of deletion ranged from
348,12 Kb to 38.97 Mb. Detected minimal deleted region comprised genes: TRIM13, miR-3613, KCNRG, DLEU2, miR-
16-1, miR-15a, DLEU1. The RB1 deletions were detected in 41 % of cases. The average size in monoallelic 13q14
deletion group was 7,2 Mb while in biallelic group was 4,8 Mb. In two cases 13q14 deletions were located in the
bigger UPD regions.
Conclusions: Our results indicate that bigger deletion including RB1 or presence of biallelic 13q14 deletion is not
sufficient to be considered as adverse prognostic factor in CLL/SLL. CytoSure Haematological Cancer and SNP array
(8x60k) can precisely detect recurrent copy number changes with known prognostic significance in CLL/SLL as well
as other chromosomal imbalances. The big advantage of this array is simultaneous detection of LOH and UPD
regions during the same test.
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Background
CLL/SLL is the most common leukemia in adults in
Western countries [1]. The clinical course of this disease
is very variable from indolent disease which is stable
for many years to very rapid progression toward ad-
vanced stages, intensive treatment and short patients
survival [2, 3]. Clinical staging systems developed by
Rai and Binet can recognize advanced stage of disease, but
they cannot predict disease course of the earlier stages [4].
Several prognostic markers have been described. Among
genetic factors, prognostic significance have mutational
status of IGVH and recurrent cytogenetic abnormalities
[5, 6]. Somatic hypermutation of the IGVH gene is ob-
served in approximately 50 % of patients, and its presence
is associated with a more benign clinical course. Chromo-
somal changes of prognostic value as del(13)(q14), tris12,
del(11)(q22.3) and del(17)(p13) can be detected in up to
50 % of patients by conventional cytogenetic analysis and
up to 80 % by routine FISH analysis [7].
Deletion of 13q14 is the most common cytogenetic
change in CLL/SLL and is detected in about 50 % of pa-
tients by FISH [5, 8]. This is a good prognostic factor if
is detected as a sole aberration in FISH analysis. In
karyotype del(13)(q14) is visible only in 8-10 % of pa-
tients, because in most of cases deletion size is sub-
microscopic [9]. Deletions vary considerably in size. The
breakpoints are heterogeneous ranging from only 300
Kb up to more than 70 Mb [10–12]. The minimal de-
leted region (MDR) is described as located distal to RB1
and comprises leukemia 2 (DLEU2) gene, which includes
microRNA miR-15a/16-1 cluster [13–15]. In recent
studies two main types of 13q14 deletions are proposed:
del(13)(q14) type I (short), which breaks close to the
miR16/15a locus and does not involve RB1; and
del(13q)(q14) type II (larger), which includes RB1 and
has been suggested to be associated with greater gen-
omic complexity and a more aggressive course [11, 16,
17]. Additionally 13q14 deletions may be heterozygous
(monoallelic) or homozygous (biallelic). Studies of serial
samples suggest that heterozygous deletion is an early
event, whereas deletion of the second copy of this region
occurs at a later stage [18, 19]. Biallelic del(13)(q14) are
present in 30 % of 13q-deleted patients [20]. They are de-
scribed as smaller and not involving RB1 [11]. The large
13q deletions are most often monoallelic, whereas a minor
proportion carries biallelic deletions. The 13q14 MDR in-
cludes miR-15a and miR-16-1, which are described as
negative regulators of the BCL2 expression [21]. One of
the documented biological functions of miR-15a and 16–1
is down-regulation of the anti-apoptotic BCL2 through
post-translational mRNA repression, which may lead to
an increased anti-apoptotic resistance [22]. This deletion
allows the CLL/SLL cells to survive. Mouse models have
formally proven the pathogenetic role of del(13q)(14) in
CLL/SLL development. Three different lines of transgenic
mice designed to mimic del(13q)(14) developed CLL/SLL
and other del(13)(q14)-associated lymphoproliferative dis-
orders [21, 23].
Array-based genomic technologies allow a genome
wide screening for genetic lesions. An aCGH array en-
ables the detection of acquired genomic copy number
variations (CNV), excluding balanced chromosomal
translocations. SNP array allows to detect the presence
of deletions which are visible as a LOH regions and re-
gions of copy-neutral LOH, which are also called unipa-
rental disomies. The resolution of array is much higher
than cytogenetic classical methods and enables detection
of submicroscopic chromosomal changes. In the current
study, we performed molecular analysis of 39 CLL/SLL
patients using CytoSure Haematological Cancer and
SNP array containing 60.000 probes. This array com-
bines on one slide long oligo aCGH probes for copy
number detection with SNP content for accurate identi-
fication of LOH also without concurrent changes in gene
copy number. The aims of the current study were detec-
tion of the size of del(13)(q14) deletion in our group of
CLL/SLL patients, comparing the size of the monoallelic




Detailed genetic examination was conducted on a group
of 40 patients, who had a loss of 13q14 region in the
tumor cells in FISH analysis. At that time of analysis
25 % of patients were treated and 75 % of patients re-
main without treatment. Characteristics of patients are
given in Table 1. The median age at the time of diagno-
sis was 62 years (range 24–78). The 55 % of the patients
were male.
Conventional G-banding analysis
Among the 40 examined patients the karyotype analysis
was successful in 35 of cases (Table 2). In 12 of patients
the karyotype was normal and 23 of patients showed
non-random karyotype aberrations. Deletion of 13q14
was karyotypically visible in two patients (cases 3,12),
monosomy 13 in one case (case 39) while translocations
with 13q14 break point were noticed twice, as
t(9;13)(q34;q14) and t(2;13)(q37;q14) (case 30 and 33).
Six patients showed deletion of 11q, three presented tri-
somy 12, one patient displayed deletion of 17p as
t(17;18)(p11.2;q11.2) translocation. Other changes had
random occurrence.
FISH analysis
In 40 CLL/SLL cases with the presence of 13q14 dele-
tion detailed analysis showed 21 of patients with
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Table 1 Clinical characteristics of 40 CLL/SLL patients








CD38 > 30 % (1)
CD38≤ 30 % (0)
1. M 55 CLL C 13 70+ 1
2. M 59 CLL C 2 54 1
3. M 73 CLL C 18 43+ 0
4. M 58 SLL C 1 27 1
5. F 75 CLL B nd 73 1
6. F 69 CLL A 84 95+ 0
7. F 61 CLL A 7 141+ 1
8. M 47 CLL A 36 80+ 0
9. M 63 CLL C 36 70+ 1
10. M 47 CLL B 30 76+ 0
11. M 47 CLL A 36 72+ 0
12. M 51 CLL A 36+ 36+ 0
13. M 34 CLL A 20 139 0
14. M 57 SLL A 3 71+ 1
15. K 54 CLL A nt 138+ 0
16. M 67 CLL C 1 17+ 1
17. M 24 CLL C 64 148 1
18. M 52 CLL B 28 83 0
19. F 63 SLL A 76 96+ 0
20. M 64 CLL C 4 42 1
21. M 41 CLL C 3 31+ 1
22. F 74 CLL A 78 111 1
23. F 63 CLL B 53 62+ 1
24. M 78 CLL C 7 32+ 0
25. M 64 CLL C 0 66+ 0
26. F 51 CLL A nt 59+ 0
27. F 60 CLL A nt 175+ 0
28. F 66 CLL A nt 16+ 0
29. F 76 CLL A nt 8+ 0
30. M 76 CLL C 30 48 1
31. F 67 CLL B 21 187+ 0
32. F 51 SLL B 60 144+ 0
33. F 64 CLL B 23 40+ 1
34. M 75 CLL A nt 39+ 0
35. F 64 CLL B 89 107+ 0
36. M 76 CLL C 0 5 0
37. F 66 CLL A nt 59+ nd
38. F 56 CLL C nt 131+ 0
39. M 53 CLL C 1 8+ 0
40. F 60 CLL C 0 39 nd
y years, mo months, nd no data, nt not treated
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Table 2 Results of karyotype analysis, FISH and IGVH mutation status of 40 CLL patients
Case no. Karyotype FISH analysis Mutational status IGVH
del 13q14 tris 12 del ATM del TP53
Cases with monoallelic deletion 13q14
1. 46,XY[10] 97 % N N N UM
2. - 97 % N 88 % N UM
3. 46,XY,del(13)(q14q32)[2]/46,XY[17] 96 % N N N UM
4. 45,XY,-6,-13,+mar [6]/ 46,XY [1] 95 % N N N UM
5. 46,XX,del(11)(q21)[10] 95 % N 99 % N UM
6. 46,XX[15] 94 % N N N UM
7. 46,XX,t(?;14)(?;q32),?add(18)(q23)[3]/46,XX[7] 93 % N N N M
8. 46,XY[12] 90 % N 92 % N UM
9. 46,XY[20]/45 ~ 46,XY,-10[2], +1 ~ 3mar[cp3] 90 % N 92 % N UM
10. - 86 % N N N M
11. 47,XY,+?2,-8,+mar[3]/46,XY[37] 84 % N N N UM
12. 46,XY,del(13)(q14q14)[9]/46,XY[11] 80 % N N N UM
13. - 71 % N N N M
14. 46,XY,del(11)(q21q24)[3]/46,XY[4] 71 % N 81 % N UM
15. 46,XX[38] 69 % N N N M
16. 46,XY,del(11)(q23)[7]/46,XY,-13,+mar[7]/ 46,XY[4] 63 % N 20 % N UM
17. 46,XY,add(1)(q?44),del(11)(q?14) [2]/46,XY [18] 58 % N 38 % N UM
18. 47,XY,+12[1]/46,XY[10] 57 % N N N UM
19. 46,XX[20] 55 % N N N UM
20. 46,XY[19] 50 % N N N UM
21. 46,XY[19] 43 % N N N UM
Cases with biallelic deletion 13q14
22. - 98 % N N 39 % UM
23. 46,XX,del(11)(q14)[10] 90 % N 90 % N UM
24. 47,XY,-6,del(12)(p11.2),+del(12)(p11.2), +der(?) (?- > ?cen-
> ?::6p25- > 6q21:6q14- > 6qter)[10] /46,XY[2]
89 % 76 % N N M
25. - 89 % N N 94 % UM
26. 46,XX[20] 87 % N N N M
27. 46,XX,t(2;7)(p11;q22)[6]/46,XX[7] 86 % N N N M
28. 45,X,-X[6]/46,XX[14] 80 % N N N M
29. 47,XX,+12[9]/46,XX[1] 56 % 41 % N N M
30. 46,XY,t(9;13)(q34;q14)[17]/46,XY[1] 90 %10 % N N N UM
31. 46,XX[20] 67 %19 % N N N M
32. 46,XX,+12,[6]/46,XX[5] 44 %32 % 80 % N N M
33. 46,XX,t(2;13)(q37;q14)[6]/46,XX[3] 40 %53 % N N N UM
34. 46,XY[13] 40 %40 % N N N M
35. 44 ~ 47,XX,+12[7]/46,XX[5] 35 %7 % 74 % N N M
36. 45,XY,der(17)t(17;18)(p11.2;q11.2),-18[2]/ 45,idem,-11,+mar[6] 26 %70 % N 27 % 93 % UM
37. 46,XX[20] 23 %21 % N N N M
38. 46,XX,del(5)(p11.2)[2]/46,XX[14] 20 %62 % N N N M
39. 46,XY,del(11)(q21)[7]/45,idem,-13 [4]/46,XY[4] 19 %76 % N 85 % N UM
40. 46,XX[5] 11 %86 % N 95 % N UM
„-‘’ no katryotype, del deletion, tris trisomy, N 100 % cells with two normal copies, M mutated IGVH, UM unmutated IGVH, bold type 13q14 biallelic deletion clone
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monoallielic and 19 of patients with biallelic deletion.
FISH results are shown in Table 2. Monoallelic deletion
was present in the range of 43–97 % of cells (average
77.8 %) in individual cases. Biallelic deletion accounted
56–98 % (average 84.4 %) of cells population in separate
cases. Pure biallelic deletion was observed in 8 patients
(42 %) and accounted 56–98 % (average 84,4 %) of cells.
The next 11 patients (58 %) had separate clones with
combined monoallelic and biallelic 13q14 deletions
(cases 30–40). Biallelic deletion clones were detected in
19–90 % of interphase nuclei (average 37.7 %) and
monoallelic deletion clones were present in the range of
7–85 % of cells (average 43.3 %) in distinct cases. Other
FISH changes were visible in 18/40 cases. The deletion
of ATM was shown in 7 out of 21 monoallelic cases and
in 4 out of 19 biallelic cases. Trisomy 12 (4 cases) as well
as TP53 deletion (3 cases) were seen only in biallelic
group.
IGVH mutational status
Analysis of the mutational status of IGVH in all 40 pa-
tients indicated 62 % of patients with unmutated (UM)
and 38 % of patients with mutated (M) IGVH (Table 2).
In monoallelic 13q14 deletion group UM status showed
81 % of patients while mutation of IGVH was detected
in 19 % of patients. All 7 patients with ATM deletion in
this group had UM IGVH. In biallelic 13q14 deletion
group 58 % of patients revealed mutated IGVH status
and 42 % unmutated status. All three patients with TP53
deletion and four patients with ATM deletion showed
UM IGVH, on the contrary all four patients with trisomy
12 had mutated IGVH.
aCGH analysis
CGH array analysis was performed on 39 available from
40 studied cases. Analysis confirmed 13q14 deletion in
all patients (Table 3, Fig. 1). The size of deletion ranged
from 348,12 Kb to 38.97 Mb. In all cases except one (case
14) deleted region contained miR-16-1 (position
50,623,109–50,623,197) and miR-15a (position 50,623,255–
50,623,337) genes (Fig. 1a). The deletions including RB1
were detected in 41 % of cases. In all 21 monoallelic cases
the loss of 13q14 was detected as a single region. The aver-
age size in monoallelic 13q14 deletion group was 7,2 Mb.
The smallest monoallelic MDR of 13q14 was 348,12 Kb
and comprised genes: TRIM13, miR-3613, KCNRG,
DLEU2, miR-16-1, miR-15a, DLEU1. The size of the biggest
monoallelic deletion was 34,82 Mb. In case 14 monoallelic
deletion of 13q14 not included miR-16-1 and miR-15a and
contained fragment of DLEU2, DLEU1, DLEU7. The dele-
tion proximal breakpoint was located 25,1 Kb telomeric dir-
ection from miR-16-1 and 24,9 Kb from miR-15a. The
deletions including RB1 were detected in 9/21 (43 %) of
monoalelic cases. Among 18 biallelic cases the same region
of deletion on the both copies of chromosome 13 was iden-
tified in 11 (61 %) cases, while in next 7 patients (39 %) two
different deleted regions were detected. The median size of
13q14 deletion in biallelic group was 4,8 Mb. The size of
the MDR was 505,17 Kb. The biggest lost region was
38,97 Mb. All cases showed deletion of miR-16-1 and miR-
15a. Deletion RB1 was identified in 7/18 (39 %) of biallelic
cases. Part of cytogenetic changes, detected by array CGH,
confirmed presence of typical chromosomal aberrations
identified by FISH (Table 4). Deletion of 11q was identified
in 8 of 11 patients with ATM deletion detected by FISH.
The smallest deletion del(11)(q22.1q23.3) was 16,96 Mb
and the biggest del(11)(q14.1q25) covered 50,41 Mb. In six
patients 11q deletion was interstitial whereas in other two
cases (17,39) deletion was terminal. Trisomy 12 was identi-
fied in 4 patients (cases 24,29,32,35). In three out of these
cases array analysis showed typical trisomy 12, while one
patient (case 24) showed partial trisomy covering whole
long arm of chromosome 12. Deletion of 17p was detected
in all three patients with one copy of TP53 in FISH (cases
22,25,36). The smallest 17p deletion del(17)(p13.3p13.1)
was 7,64 Mb and in the biggest del(17)(p13.3p11.2) com-
prising almost whole short arm of chromosome 17 was
21,08 Mb. Additional changes, with respect to those de-
tected by FISH, were similar in both groups with monoalle-
lic and biallelic deletion of 13q14. The most common
aberrations included losses and gains of different regions of
1q (4 cases), gains of 2p (3 cases) and 19q13 (3 cases) as
well as changes of Xq (3 cases). The minimal gained region
on 2p16.1-p15 (case 21) was 3,23 Mb and covered genes:
FANCL, EIF3FP3, BCL11A, PAPOLG, REL, NONOP2,
PUS10, PEX13, KIAA1841, AHSA2, USP34. Rest of copy
number alternations had random occurrence. Additional
copy number aberrations, in relation to the already de-
scribed, were detected in 12 patients with monoallelic
group and in 10 patients in biallelic group, with total num-
ber of alternation equal 20 in each group.
SNP analysis
SNP analysis was performed on 25/39 cases of which
13/25 showed aberrant SNP pattern (Table 4). Chromo-
some 13 changes were detected in 7/25 patients. In five
cases (2,7,12,13,39) SNP distribution confirmed big
13q14 deletions as LOH regions. In six cases
(2,5,8,9,14,39) SNP analysis showed LOH in 11q deletion
regions. In two patients (25,39) LOH regions matched
deletions of 8p, 17p and 12p, respectively. Regions of no
changes in copy number but with aberrant pattern in
SNP analysis were considered as UPD. In two cases
(25,29) 13q14 deletions were located in the bigger (at
least 10 Mb larger than deletion regions) copy neutral
LOH regions (Fig. 2). In case 25 this UPD covered whole
chromosome 13. Remaining UPD regions included:
2p25.3-p14, 3p26.1-p24.3, 7q21.11-q22.1, 17q21.2-
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Table 3 Results of chromosome 13 array CGH analysis of 39 CLL patients
Case No. Position of 13q14 deletion Size of deletion miR 15a/16-1 deletion RB1 deletion
Monoallelic
5. arr 13q14.2q14.3 (50,561,374-50,909,490)x1 348,12 Kb + -
18. arr 13q14.2q14.3 (50,575,469-51,213,898)x1 638,43 Kb + -
14. arr 13q14.2q14.3 (50,648,212-51,296,645)x1 648.43Kb - -
10. arr 13q14.2q14.3 (50,532,206-51,502,524)x1 970,32 Kb + -
11. arr 13q14.2q14.3 (50,506,929-51,502,525)x1 995,60 Kb + -
17. arr 13q14.2q14.3 (49,975,238-51,581,258)x1 1,61 Mb + -
6. arr 13q14.2q14.3 (50,547,426-52,293,661)x1 1.75 Mb + -
19. arr 13q14.2q14.3 (49,667,023-51,766,748)x1 2,10 Mb + -
21. arr 13q14.2q14.3 (49,466,784-51,789,968)x1 2,32 Mb + -
1. arr 13q14.2q14.3 (48,796,715-51,126,898)x1 2,33 Mb + -
4. arr 13q14.2q14.3 (49,643,767-52,415,185)x1 2,77 Mb + -
20. arr 13q14.2q14.3 (48,852,953-52,024,641)x1 3,17 Mb + -
9. arr 13q14.2q14.3 (48,476,853-51,937,417)x1 3,46 Mb + +
3. arr 13q14.2q14.3 (48,229,933-51,827,408)x1 3,60 Mb + +
8. arr 13q14.2q14.3 (48,875,709-52,722,490)x1 3,85 Mb + +
16. arr 13q14.13q14.3 (47,067,473-52,293,661)x1 5,23 Mb + +
7. arr 13q14.11q14.3 (44,820,708-51,472,821)x1 6.65 Mb + +
12. arr 13q14.12q21.31 (45,230,434-65,085,253)x1 19,85 Mb + +
15. arr 13q13.3q21.2 (37,178,772-60,025,895)x1 22,85 Mb + +
2. arr 13q13.3q21.33 (39,377,596-71,248,873)x1 31,87 Mb + +
13. arr 13q13.3q21.33 (36,430,114-71,248,873)x1 34,82 Mb + +
Biallelic
33. arr13q14.2q14.3 (50,659,348-51,164,513)x0 505,17Kb - -
arr 13q14.2q14.3 (50,337,728-51,897,968)x0 1,56 Mb + -
38. arr 13q14.2q14.3 (50,575,469-51,360,705)x0 785,24 Kb + -
25. arr 13q14.2q14.3 (50,597,418-51,454,330)x0 856.91Kb + -
27. arr 13q14.2q14.3 (50,575,469-51,441,414)x1 865,95 Kb + -
24. arr 13q14.2q14.3 (50,561,374-51,441,414)x0 880,04 Kb + -
26. arr 13q14.2q14.3 (50,575,469-51,472,821)x0 897,35 Kb + -
35. arr 13q14.2q14.3 (50,575,469-51,502,524)x1 927,06 Kb + -
arr 13q14.2q14.3 (48,754,460-52,536,626)x1 3,78 Mb + +
29. arr 13q14.2q14.3 (50,575,469-51,523,591)x1 948,12 Kb + -
37. arr 13q14.2q14.3 (50,532,206-51,502,524)x1 970,32 Kb + -
28. arr 13q14.2q14.3 (50,484,540-51,524,424)x1 1,04 Mb + -
arr 13q14.2q14.3 (50,241,416-51,524,424)x1 1,28 Mb + -
34. arr 13q14.2q14.3 (50,484,540-51,572,737)x1 1.09 Mb + -
32. arr 13q14.2q14.3 (50,408,714-51,572,737)x0 1,16 Mb + -
arr 13q13.3q14.3 (39,596,989-51,624,965)x1 12,03 Mb + +
31. arr 13q14.2q14.3 (50,305,714-51,469,354)x1 1,16 Mb + -
arr 13q12.3q21.31 (31,346,665-64,680,548)x1 33,33 Mb + +
36. arr 13q14.2q14.3 (49,579,386-51,404,793)x1 1,83 Mb + -
40. arr 13q14.2q14.3 (49,667,023-51,641,879)x1 1,97 Mb + -
arr 13q14.2q14.3 (48,783,721-52,722,490)x1 3,94 Mb + +
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q21.33, 7q32.2-q36.6, 7q35-q36.3, 12q23.1-q24.13. In
case 25 big UPD region (65 Mb) on 2p covered smaller
deletion (7,27 Mb).
Survival and time to treatment
Clinical follow-up of 40 CLL patients ranged from 8 to
187 months, with a median follow-up of 71 months. At
the time of last follow-up 5 of 21 patients in monoallelic
group and 4 of 19 patients in biallelic group had died.
Time to treatment (TTT) for all patients ranged from 8 to
175 months, with a median TTT of 59 months. We inves-
tigated the relationship of 13q14 deletion status
(monoallelic vs. biallelic; monoallelic vs. biallelic excluding
cases with TP53 and ATM deletion), size of 13q14 deletion
(13q14 with RB1 deletion vs.13q14 without RB1 deletion)
and IGVH mutation status with TTT and overall survival
(OS) (Table 5). This analysis showed that only mutational
status has statistically significant relation (Fig. 3). Me-
dian TTT was shorter in the unmutated group
(18 months vs. 89 months, P = 0.003, 95 % CI: 0–45
and 16–162). Median OS was also shorter in IGVH
unmutated group (110 months, P = 0.003; 95 % CI:
62–160) compared to the mutated group (median has
not been reached).
Table 3 Results of chromosome 13 array CGH analysis of 39 CLL patients (Continued)
22. arr 13q14.2q14.3 (48,841,955-50,976,908)x0 2,13 Mb + +
arr 13q14.13q14.3 (46,934,009-52,663,754)x0 5,73 Mb + +
30. arr13q14.2q14.3 (48,801,028-51,680,357)x0 2,88 Mb + +
39. arr 13q14.11q31.1 (41,246,428-80,220,989)x1 38.97 Mb + +
In biallelic 13q14 deletion group digit x1 suggests monoallelic change, but this value is associated with lower percentage of cells with biallelic deletion in whole
cell population
Fig. 1 Pattern of chromosome 13q deletions of 39 CLL/SLL patients detected by CGH array. a monoallelic deletions (black lines); b biallelic
deletion (grey lines indicate deletion size on the second chromosome 13 copy, if was different than on the first copy identified in array analysis)
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Table 4 Results of aCGH analysis of copy number variations, and SNP results revealing loss of heterozygosity, and uniparental
disomy status of 39 CLL patients
Case no. CNV LOH UPD















No changes No changes
arr 19q13.41(52,273,095-52,540,512)x3 (267,42
Kb)
4. arr 13q14.2q14.3 (49,643,767-52,415,185)x1
(2,77 Mb)
No changes No changes
5. arr 4p15.2(25,475,860-26,940,881)x1 (1,47 Mb) 7q35q36.3(147,741,217-157,731,561)x2
(9,99 Mb)









arr Xp22.31(6,493,087-8,034,106)x3 (1,54 Mb)
arr Xq28(155,169,566-155,234,551)x3 (64,98 Mb)
6. arr 13q14.2q14.3(50,547,426-52,293,661)x1
(1.75 Mb)
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Table 4 Results of aCGH analysis of copy number variations, and SNP results revealing loss of heterozygosity, and uniparental












15. arr 13q13.3q21.2 (37,178,772-60,025,895)x1
(22,85 Mb)
n.t. n.t






























No changes No changes
arr 13q14.2q14.3(49,466,784-51,789,968)x1
(2,32 Mb)












24. arr 6p25.3(209,906-1,318,308)x3 (1,11 Mb) n.t. n.t
arr 6p21.1-q13(45,388,754-72,422,581)x1
(27,03 Mb)
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Table 4 Results of aCGH analysis of copy number variations, and SNP results revealing loss of heterozygosity, and uniparental































arr 19q13.43(56,465,808-59,057,705)x3 (2.59 Mb)
arr Xq28(154,844,440-155,234,551)x2 (390.11Kb)
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Discussion
Only 8–10 % of 13q14 deletion can be detected in
karyotype analysis in CLL/SLL patients because of its
submicroscopic size [9]. By FISH method deletion of
13q14 is revealed in 50 % of patients. This technique
can show the presence or absence of the deletion with-
out information about the size of the lost region. Here
we present detailed size analysis of 39 CLL/SLL patients
performed by CytoSure Haematological Cancer and SNP
array. The smallest identified 13q14 deleted region was
348,12 Kb. This observation is concordant with other
studies, were MDRs were similar sizes and also comprised
DLEU1, DLEU2 and DLEU7 genes [12, 24, 25]. In the
most CLL/SLL cases 13q14 deletion leads to loss of two
microRNA genes miR-15a and miR-16-1, which are con-
sidered to be a key genes of this deletion. Studies on the
structure of genes in 13q14 deleted region revealed that in
MDR is located DLEU2 gene which encodes part of first
exon of DLEU1 as well as two microRNA miR-15a and
miR-16-1 which are located between exons 2 and 5 of the
DLEU2 [26]. Previous data reported downregulation of
miR-15a and miR-16-1 in about 65 % of CLL cases with
13q14 deletion [15]. However recent reports describe
much smaller proportion of patients with downregulation
Table 4 Results of aCGH analysis of copy number variations, and SNP results revealing loss of heterozygosity, and uniparental
disomy status of 39 CLL patients (Continued)







No changes No changes










































Changes are described in a cytogenetic region, molecular position and size in base pairs
CNV copy number variations, LOH loss of heterozygosity, UPD uniparental disomy, n.t not tested,aUPD of whole chromosome 13 with deletion 13q14
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of both micoRNAs which accounts near 10 % of CLL
and mostly in patients with biallelic 13q14 deletion
[11, 27, 28]. MiR-15a and miR-16-1 expression was
inversely correlated to BCL2 expression in CLL [22].
BCL2 is an oncogene promoting survival by inhibiting
cell death. In light of recent research that do not in-
dicate a reduced expression of miR-15a and miR-16-1
in the majority of patients with 13q14 deletion but in
the same time shows elevated level of BCL2 protein
in patients with monoallelic and biallelic 13q14 dele-
tion, this point out that the regulation of BCL2 pro-
tein levels is more complex and do not mainly
determined by miR-15a and miR-16-1 levels [28]. In
our study one patient with 13q14 deletion detected
by FISH retained both copies of miR-15a and miR-
16-1. The proximal deletion breakpoint was situated
telomeric direction relative to both microRNA genes.
Similar phenomenon of 13q14 deletions without loss
of miR-15a and miR-16-1 were described by Mosca
et al. and Edelmann et al. [12, 24].
Deletion of the second copy of D13S319 locus in CLL/
SLL is well documented. Biallelic 13q14 deletion can
have the same or different sizes [16, 17, 24, 29]. Gener-
ally, biallelic deletions of 13q14 are reported as smaller
in comparison with monoallelic deletions [10, 12, 24].
Our results indicate that biallelic 13q14 deletion regions
can be the same or different sizes on both copies of
chromosome 13. Concurrently the median size of dele-
tion in biallelic group was much smaller than in monoal-
lelic group what is consistent with the literature data.
Some authors define biallelic 13q14 deletion presence as
well as bigger deletion region covering RB1 (called type II
deletions) as adverse prognostic factors connected with fas-
ter lymphocyte growth and associated with inferior progno-
sis [11, 30, 31]. The statistical analysis of our data regarding
to TTT and OS do not confirm this observations. Our data
Fig. 2 CytoSure Haematological Cancer and SNP array of two cases: 25 (a) and 29 (b). The overview window shows ideogram of chromosome
13, below result of aCGH as a copy number variations (CNV) indicating deletion of 13q14, underneath big red blocks demonstrating uniparental
disomy (UPD) regions revealed in SNP analysis. Lower section shows magnification of aCGH analysis (CNV)
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are in line with results of other groups, which showed that
loss of second copy of 13q14 is not enough to cause a
worst prognosis in CLL and there is not any significant dif-
ference in the baseline characteristic and TTT between pa-
tients with shorter (biallelic) and wider (monoallelic) 13q14
deletions [12, 25, 32, 33].
The presence of all cytogenetic aberrations identified
by FISH was confirmed by aCGH. Only in three cases
deletion 11q was not recognized in aCGH study. In two
patients percentage of cells with ATM deletion was less
than 30 % what was below the sensitivity of the method
and one patient with del 11q was not analysed by aCGH.
Among the most frequent additional changes revealed
by aCGH the most significant was gain of 2p detected in
three patients. This aberration is described as recurrent
genetic change in CLL associated disease progression.
Some studies defined in common 2p gained region pres-
ence of REL, MYCN and ALK oncogenes [34, 35]. The
results of other research by Pfeifer and Edelmann delin-
eated much smaller minimal 2p gained regions, which
included 2p16 (size 3,5 Mb) and 2p16.1-p15 (size
1,9 Mb), respectively. Both regions contained two
Table 5 Statistical analysis of 40 CLL/SLL patients
Genetic feature Number of patients Median TTT (months) Median OS (months)
TTT OS
IGHV status unmutated 24 25 18 110
mutated 15 15 89 Not reached
P-value p = 0,003 p = 0,003
13q14 deletion monoallelic 20 21 19 140
biallelic 19 19 53 148
P-value p = 0,203 p = 0,511
13q14 deletion without delTP53 monoallelic 20 21 19 140
biallelic 16 16 60 Not reached
P-value p = 0,099 p = 0,237
13q14 deletion without del TP53 and del ATM monoallelic 14 14 19 140
biallelic 14 14 60 Not reached
P- value p = 0,141 p = 0,444
13q14 deletion with Rb deletion 16 16 21 140
without Rb deletion 23 24 30 148
P- value p = 0,426 p = 0,942
TTT time to treatment, OS overall survival
Fig. 3 Statistical analysis of 40 CLL/SLL patients. a. Time to treatment patients with and without IGVH mutation (P = 0.003). b . Overall survival
patients with and without IGVH mutation (P = 0.003)
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oncogenes REL and BCL11A [24, 30]. Our results are
consistent with these observations. The size of minimal
detected 2p16.1-p15 gained region was 3.23 Mb and in-
cluded REL and BCL11A oncogenes. In second patient
duplicated 2p16.1-p14 region was bigger and covered
7.27 Mb, consisting REL and BCL11A, but not MYCN
and ALK. Third patient revealed duplication of the
whole 2p. Additional copies of 2p in CLL are associated
with unmutated IGVH, frequent occurrence of deletion
11q and 17p and advanced stage of disease [30, 34, 35].
In our studied group all three patients revealed unmu-
tated IGVH and Binet stage C. One patients had deletion
of ATM and other deletion of TP53. The presence of 2p
gain often is accompanied by adverse genetic changes
and more advanced stage of disease what confirms the
poor prognosis of this change.
There is an association between prognosis and the
somatic hypermutation status of the IGHV genes in CLL
[5, 6]. Patients with unmutated IGHV display a more ag-
gressive disease, high-risk cytogenetics and a poor out-
come, while mutated IGHV are associated with a more
favourable clinical course with long OS. In our analysed
group all CLL/SLL patients with unfavourable cytogen-
etic prognostic factors as deletions of TP53 and ATM
had unmutated IGVH status, what confirms poor prog-
nosis. On the contrary all patients with trisomy 12,
which is associated with an intermediate prognosis and a
good response to treatment, had mutated IGVH. Muta-
tional status of IGVH was the only factor in our study
with statistical significance in relation to TTT and OS.
In both analysis patients with unmutated IGVH had
shorter TTT and OS.
SNP array can identify LOH regions as well as copy
neutral LOH, which are also called UPD in cancer gen-
ome. These chromosomal regions are characterized by
loss of heterozygosity and normal copy number of DNA
segments which are not homozygous in the germ-line or
normal somatic genome [36]. Due to a lack of change in
the copy number, UPD remains undetected by karyotyp-
ing, FISH and aCGH. The CytoSure Haematological
Cancer and SNP array (8x60k) can identify on one slide
during the same experiment both copy number varia-
tions and SNP, which enables detection of corresponding
LOH and UPD regions. A significant advantage of this
method is also no need to use the corresponding control
DNA from the same patient. In our analysis big LOH re-
gions matched to deletion regions confirming presence
of these changes by using another method. In most cases
LOH corresponded to deletions with prognostic signifi-
cance in CLL as 11q, 13q and 17p, what is in accordance
with previous SNP array studies in CLL [24, 29]. UPD
regions, showing changes in SNP distribution but not in
copy number, were included in our analysis when cov-
ered regions bigger than 10 Mb [29]. In two patients
with biallelic 13q14 deletion we have detected UPD re-
gions. In one patient this neutral copy number LOH
covered whole chromosome 13. In the second case small
biallelic deletion was located in much bigger UPD re-
gion. Similar observation regarding the coexistence of
UPD and biallelic 13q14 deletions was reported by other
authors [16, 24, 29, 30]. The same size of deletion in
both cases with UPD on chromosome 13 confirms du-
plication of deleted region, which is different from bialle-
lic deletions with different sizes which probably arisen
by two events. Biallelic 13q14 deletions of the same size
but without copy neural LOH can be created by other
genetic mechanism or the second deletion is invisible in
array analysis because of to low percentage of clone with
the second loss. UPD containing deletions may implicate
the elimination of tumor suppressor genes. In one pa-
tient big UPD segment covered small gain region on 2p.
In this case UPD is connected with gain of two onco-
genes REL and BCL11A and hypothetically can concern
unmutated gene copies or gene mutations increasing the
activity of oncogenes. The significance of a common oc-
currence of UPD and copy number changes is not
exactly defined, but can be related with clonal evolution
favouring alleles with greater growth potential.
In the summary, the CytoSure Haematological Cancer
and SNP array (8x60k) can precisely detect recurrent
copy number changes with known prognostic signifi-
cance in CLL/SLL as well as other chromosomal imbal-
ances. The big advantage of this array is simultaneous
detection of LOH and UPD regions during the same
test. Resolution of this technique can accurately define
size of 13q14 deletion with detection of miR-15a and
miR-16-1 involvement. The average size of monoallelic
13q14 deletions was larger than in biallelic group. Our
results show that bigger deletion including RB1 or pres-
ence of biallelic 13q14 deletion is not sufficient to be
considered as adverse prognostic factor. Uniparental
disomies especially on chromosome 13 are quite fre-
quent phenomenon in CLL patients, especially with bial-
lelic 13q14 deletion and its impact on the disease course
has to be determined.
Methods
Patients
The study group included 40 patients with diagnosis
of CLL/SLL. All patients were evaluated in MSCM
Institute and Cancer Center, Warsaw from February
2005 to November 2014. All samples had approval of
the Bioethics Committee of the Oncology Centre -
Institute Maria Sklodowska-Curie. The diagnosis of
CLL/SLL was established between September 1999
and June 2014, according to the current WHO classi-
fication [29, 37]. For the present study patients were
selected on the basis of the presence of 13q14
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deletion detected by routine FISH analysis and the
availability of specimens.
Cell culture and cytogenetics
Fresh blood (CLL) or biopsy samples (SLL) were fixed
directly or cultured in a 5 % CO2 atmosphere at 37 °C.
The growth medium was DMEM (Lonza, Verviers,
Belgium), enriched with 15 % fetal calf serum (GIBCO,
Invitrogen GmbH, Karlsruhe, Germany) and antibiotics.
Blood was cultured for 72 h and stimulated in two vari-
ants: with TPA (phorbol 12- myristate 13-acetate)(Sigma-
Aldrich, Steinheim, Germany) or with DSP-30 (2 μM;
TIBMolBiol, Berlin, Germany) together with IL-2 (200 U/
ml; R&D Systems, Minneapolis, MN, USA). For biopsy
material following cell cultures were performed: direct,
24 h without mitogens and 72 h with TPA or with DSP-30
plus IL-2. Cells for cytogenetic and FISH analysis were
harvested according to standard procedures, cultures were
treated with colcemid, afterwards cells were exposed to
hypotonic solution and fixed in Cornoy’s solution. Chro-
mosomes were Wright stained for G,C-banding. At least 7
metaphases were analyzed. Karyotypes were classified ac-
cording to the International System for Human Cytogen-
etic Nomenclature (2013)[38].
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on tumor cells obtained
directly from a biopsy or after unstimulated or stimu-
lated in vitro culture. FISH was performed to establish
the status of TP53, ATM, centromere12 and D13S319
region. Following commercially available probes were
used: LSI TP53, LSI ATM, CEP12, LSI D13S319 and LSI
13q34 (Vysis Abbott Molecular, Downers, Grove, IL,
USA). Loss of one D13S319 signal was equal with mono-
allelic 13q14 deletion and loss of both D13S319 signals
was equivalent biallelic 13q14 deletion. The procedures
for all commercial probes were applied according to the
manufacturer’s protocol. At least 100 interphase cells were
analysed. Slides were analyzed using an epifluorescence
microscope Axioskop2 (Carl Zeiss, Jena, Germany) and
documented by ISIS Imaging System (Metasysytems,
Altlussheim, Germany).
Array comparative genomic hybridization (aCGH)
DNA was extracted from fresh biopsy material or cyto-
genetic fixed cell suspension by QIAmp DNA Blood
Mini Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s recommendation. For aCGH analysis CytoSur-
eTM Haematological Cancer and SNP Array (8x60k)
(Oxford Gene Technology (OGT), Yarnton, Oxford OX5
1PF UK) was used. On this array average gene resolution
was 68 Kb and SNP resolution was equal 30 Mb. The
procedure of aCGH was performed following the manu-
facturer’s protocol. The reference DNA was from two
pools of normal individuals (male and female), run as a
same-sex control. Each patient and reference DNA was
labeled with Cy3 and Cy5, respectively. Purification of
labeled products, hybridization, and post-wash of the
array was carried out according to OGT’s recommenda-
tion and with their proprietary solutions. Array slides
were scanned with Agilent’s DNA Microarray Scanner
and extraction software (Agilent, Santa Clara, USA).
aCGH analysis
CytoSure Interpret software 020022 (OGT) was used for
analysis of array data. The program uses the Circular
Binary Segmentation (CBS) algorithm to generate seg-
ments along the chromosomes that have similar copy
number relative to reference chromosome [39]. Aver-
aging of the segments is with median value of all seg-
ments on a chromosome as the baseline. Deletion or
duplication calls are made using the log2 ratio of each
segment that has a minimum of four probes. Threshold
factor for deletions was set as a log2 ratio of −0.6 that is
less stringent than the theoretical log2 score of −1 (het-
erozygous deletion log2(1/2) = −1; No change in allele
number log2(2/2) = 0; heterozygous duplication log2(3/
2) = 0.59). The software uses the Derivative Log Ratio
(DLR) Spread, which is used as a quality control check.
This metric calculates probe-to-probe log ratio noise of
an array and hence of the minimum log ratio difference
required to make reliable amplification or deletion calls.
A DLR of 0.08–0.19 is accepted, 0.20- 0.29 is borderline,
and ≥0.30 is rejected. The DLR for all arrays was scored
by this scale. Genes positions were identified according
to human genome build hg19. The software calculated
the total percentage homozygosity of each sample con-
taining SNP data based on the method described by
Sund et al.[40].
PCR amplification of immunoglobulin rearrangements
and sequence analysis
Genomic DNA was isolated from cell culture using the
QIAamp DNA Extraction Kit (Qiagen, Hilden, Germany)
according to the kit’s instructions. Immunoglobulin heavy
chain variable gene (IGHV) rearrangements were ampli-
fied by the Multiplex polymerase chain reaction (PCR), fol-
lowing the BIOMED–2 protocol [41]. In this instance,
each reaction contained a mixture of six family-specific
framework region (FR) primers (VH1-VH6) and an anti-
sense primer (JH). However, for cases, where mutations
weren’t detected, IGHV rearrangement were determined
by amplifying DNA using the appropriate leader primers.
The cycling conditions were: an initial denaturation step at
95o C for 7 min, followed by 35 cycles at 94o C for 30 s,
60o C for 30 s and 72o C for 30 s, with a final extension
step at 72o C for 7 min and ended at 4o C. The PCR prod-
ucts were determined by 2 % agarose gel electrophoresis.
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DNA bands were observed on the UV transilluminator
and documented using the Bio-RAD software. PCR prod-
ucts were then purified using a mixture of two enzymes:
alkaline phosphatase and exonuclease I (in the ratio 1:1).
The purified amplicons were sequenced using the Big Dye
Terminator and analysed with an automatic ABI PRISM
3100 Sequencer (Life Technology, Foster City, SA). Nu-
cleotide sequences were analysed using the ImMunoGe-
neTics database (IMGT) [42]. Mutational status was
identified by comparing the sequence of the IGHV of the
patient with the most homologous germline V sequence.
IGHV sequences with <98 % homology to a germline were
defined as mutated, while sequences with of homology of
98 % or higher were considered as unmutated.
Statistical methods
TTT was measured from the date of diagnosis until first
treatment or, for untreated patients, to last follow-up
(censored observation). OS was estimated from the date
of diagnosis to the death (whatever the cause) or the last
follow up. The cumulative probability of OS and TTT
were plotted as curves according to the Kaplan-Meier
method. A log-rank (Mantel-Cox) test was performed
for all categorical variables. A P−value of <0.05 was con-
sidered as statistically significant.
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